BAJAJ BROKING

Notification close image
No new Notification messages
card image
Smartworks Coworking Spaces IPO is Open!
Apply for the Smartworks Coworking Spaces IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

FDA Flags 6 Observations in Lupin’s New Jersey Facility Inspection

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Lupin's Somerset, NJ facility, inspected by the FDA from May 7 to May 17, 2024, received Form-483 with six observations. The company's Q4 FY24 saw a 41.38% net profit drop to ₹359.43 crore on a 3.64% revenue decline to ₹4895.11 crore.

Lupin News Today

Lupin Limited, a pharmaceutical company known for its innovation, underwent a pre-approval inspection by the US Food and Drug Administration (FDA) at its manufacturing facility in Somerset, New Jersey.

Explore: Lupin Limited Share Price

Form-483 Issued with Six Observations

The inspection was carried out from May 7 to May 17, 2024, and resulted in the issuance of a Form-483 by the FDA. This form highlighted six observations made by the inspectors regarding potential regulatory violations.

Response to FDA Observations

Lupin promptly responded to the FDA's observations, pledging to address them comprehensively. As per regulatory requirements, the company will provide a detailed corrective action plan within the specified timeframe to ensure compliance with FDA regulations.

Additional ReadShare Market News

Lupin’s Q4 Results

In the fourth quarter of FY24, Lupin witnessed a significant decline in its consolidated net profit, plummeting by 41.38% to ₹359.43 crore. Additionally, the company's revenue from operations saw a decrease of 3.64% to ₹4895.11 crore compared to Q4 FY23.

Regulatory Disclosure

Lupin disclosed the outcome of the FDA inspection in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This communication was made to the Bombay Stock Exchange (BSE), ensuring transparency and adherence to regulatory norms.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|